Search
Search Results
-
Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis
PurposeIn the Netherlands yearly more than 5000 patients are diagnosed with non-muscle invasive bladder cancer (NMIBC). With a specificity of 88.0%...
-
Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review
BackgroundBladder cancer detection and follow-up is based on cystoscopy and/or cytology, but it remains imperfect and invasive. Current research...
-
Investigation of Atypical Cell Parameter in the Surveillance of Patients with NMIBC; Initial Outcomes of a Single Center Prospective Study
Objective: To investigate how well the Sysmex automated urine-analyzer’s atypical-cell parameter can predict oncological outcomes when compared to...
-
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
ObjectivesThe treatments for high-grade non-muscle invasive bladder cancer (NMIBC) vary between bladder preserving intravesical approaches and...
-
Nicht-muskelinvasives Harnblasenkarzinom (NMIBC) – Rezidivprophylaxe bei geringem und intermediärem Risiko
BackgroundLow- and intermediate-risk non-muscle invasive bladder cancer (NMIBC) is characterized by a relatively high risk of recurrence and adjuvant...
-
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
PurposeRadical cystectomy (RC) is the standard treatment for high-risk non muscle-invasive bladder cancer (NMIBC) failing first BCG treatment. A...
-
Interruption of BCG Therapy for NMIBC During COVID-19 Crisis, Dilemma in Its Continuation: a Review of Available Evidence and Suggested Management Strategies
The COVID-19 disease, caused by SARS-CoV-2 virus, has been one of the worst pandemics ever to hit the human mankind. Undoubtedly the start of the...
-
Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)
BackgroundIntravesical bacillus Calmette-Guérin (BCG) fails in a considerable proportion of non-muscle invasive bladder cancer (NMIBC) patients...
-
-
-
Oncological Monitoring of NonMuscle Invasive Bladder Cancer (NMIBC)
Bladder cancer is the most common urinary tract malignancy and the fifth leading new cancer diagnosis in the United States. Nonmuscle-invasive...